Study to Evaluate Safety and Pharmacokinetics of ARRY-403 in Patients With Type 2 Diabetes



Status:Archived
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:August 2009

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized, Double-Blind (Sponsor Excepted), Placebo-Controlled Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Orally Administered ARRY-403 in Patients With Type 2 Diabetes


Phase 1 study is designed to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics
(PD) of multiple ascending doses of ARRY-403 provided to patients with type 2 diabetes. The
study will consist of a Screening period, a Diary and Glucometer Dispensing Visit, a Washout
Period, a Confinement Period in the Clinical Research Unit, and a Follow-up/Termination
Visit.



We found this trial at
2
sites
Profil Institute for Clinical Research
Chula Vista, California 91911
?
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Cetero Research
Fargo, North Dakota 58104
?
mi
from
Fargo, ND
Click here to add this to my saved trials